nach oben

Erschienen in:

01.02.2011 | Original Paper

An assessment of parathyroid hormone, calcitonin, 1,25 (OH)₂ vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors

verfasst von: Nasser Shakhssalim, Kobra Roohi Gilani, Mahmoud Parvin, Peyman Mohammadi Torbati, Amir H. Kashi, Mohaddeseh Azadvari, Banafsheh Golestan, Abbas Basiri

Erschienen in: Urolithiasis | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to investigate the serum levels of parathyroid hormone (PTH), calcitonin, 1,25 (OH)₂ vitamin D3, estradiol and testosterone in male patients with active renal calcium stone disease compared with controls and investigate their relationship with serum/urinary biochemistry. Male active renal calcium stone formers (ASF) were enrolled from December 2008 to April 2009. Controls were selected from age and sex matched individuals. Two 24-h urine samples and a blood sample were withdrawn from each participant while they were on free diet. Serum 1,25 (OH)₂ vitamin D3 levels in the ASF and control groups were 127 ± 40 and 93 ± 35 pmol/l (p < 0.001). Serum levels of PTH, calcitonin, estradiol and testosterone were not statistically different between the ASF and control groups (all p > 0.05). Serum 1,25 (OH)₂ vitamin D3 was associated with higher urinary excretion of calcium and phosphorus in ASF patients. Serum levels of calcitonin were related to less urinary excretion of calcium in the control group. Serum testosterone was related to higher urinary excretion of uric acid in ASF patients and to higher urinary excretion of oxalate in the control group. 1,25 (OH)₂ Vitamin D3 is an important hormone in the pathogenesis of recurrent renal calcium stone disease and could increase renal stone risk by increasing the urinary excretion of calcium and phosphorus. There is a possibility of testosterone involvement in the pathogenesis of renal stones through higher urinary uric acid and oxalate excretion.

Bihl G, Meyers A (2001) Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 358:651–656CrossRefPubMed

Griffin DG (2004) A review of the heritability of idiopathic nephrolithiasis. J Clin Pathol 57:793–796CrossRefPubMed

Mossetti G, Rendina D, Viceconti R, Manno G, Guadagno V, Strazzullo P, Nunziata V (2004) The relationship of 3′ vitamin D receptor haplotypes to urinary supersaturation of calcium oxalate salts and to age at onset and familial prevalence of nephrolithiasis. Nephrol Dial Transplant 19:2259–2265CrossRefPubMed

Relan V, Khullar M, Singh SK, Sharma SK (2004) Association of vitamin D receptor genotypes with calcium excretion in nephrolithiatic subjects in northern India. Urol Res 32:236–240CrossRefPubMed

Scott P, Ouimet D, Valiquette L, Guay G, Proulx Y, Trouve ML, Gagnon B, Bonnardeaux A (1999) Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 10:1007–1013PubMed

Smith LH (1987) Pathogenesis of renal stones. Miner Electrolyte Metab 13:214–219PubMed

Robertson WG (1986) Pathophysiology of stone formation. Urol Int 41:329–333CrossRefPubMed

Giannini S, Nobile M, Castrignano R, Pati T, Tasca A, Villi G, Pellegrini F, D’Angelo A (1993) Possible link between vitamin D and hyperoxaluria in patients with renal stone disease. Clin Sci (Lond) 84:51–54

Khanam A, Rahman MA (1993) Parathyroid hormone in urinary stone patients. Mol Cell Biochem 121:1–4CrossRefPubMed

10.

von Lilienfeld-Toal H, Bach D, Hesse A, Franck H, Issa S (1982) Parathyroid hormone is normal in renal stone patients with idiopathic hypercalciuria and high fasting urinary calcium. Urol Res 10:205–207CrossRef

11.

Chen WC, Wu HC, Lu HF, Chen HY, Tsai FJ (2001) Calcitonin receptor gene polymorphism: a possible genetic marker for patients with calcium oxalate stones. Eur Urol 39:716–719CrossRefPubMed

12.

Goodman HO, Holmes RP, Assimos DG (1995) Genetic factors in calcium oxalate stone disease. J Urol 153:301–307CrossRefPubMed

13.

Shainkin-Kestenbaum R, Winikoff Y, Paran E, Lismer L (1984) The role of calcitonin in calcium stone formation. Nephron 38:154–155CrossRefPubMed

14.

Fuss M, Pepersack T, Corvilain J, Bergmann P, Simon J, Body JJ (1991) Calcitonin secretion in idiopathic renal stone formers. J Bone Miner Res 6:35–38CrossRefPubMed

15.

Jarrar K, Amasheh RA, Graef V, Weidner W (1996) Relationship between 1,25-dihydroxyvitamin-D, calcium and uric acid in urinary stone formers. Urol Int 56:16–20CrossRefPubMed

16.

Gascon-Barre M, D’Amour P, Dufresne L, Perreault JP (1985) Interrelationships between circulating vitamin D metabolites in normocalciuric and hypercalciuric renal stone formers. Ann Nutr Metab 29:289–296CrossRefPubMed

17.

Netelenbos JC, Jongen MJ, van der Vijgh WJ, Lips P, van Ginkel FC (1985) Vitamin D status in urinary calcium stone formation. Arch Intern Med 145:681–684CrossRefPubMed

18.

Ding C, Cicuttini F, Parameswaran V, Burgess J, Quinn S, Jones G (2009) Serum levels of vitamin D, sunlight exposure, and knee cartilage loss in older adults: the Tasmanian older adult cohort study. Arthritis Rheum 60:1381–1389CrossRefPubMed

19.

Hammar ML, Berg GE, Larsson L, Tiselius HG, Varenhorst E (1987) Endocrine changes and urinary citrate excretion. Scand J Urol Nephrol 21:51–53CrossRefPubMed

20.

Johnson CM, Wilson DM, O’Fallon WM, Malek RS, Kurland LT (1979) Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 16:624–631CrossRefPubMed

21.

Dey J, Creighton A, Lindberg JS, Fuselier HA, Kok DJ, Cole FE, Hamm LL (2002) Estrogen replacement increased the citrate and calcium excretion rates in postmenopausal women with recurrent urolithiasis. J Urol 167:169–171CrossRefPubMed

22.

Heller HJ, Sakhaee K, Moe OW, Pak CY (2002) Etiological role of estrogen status in renal stone formation. J Urol 168:1923–1927CrossRefPubMed

23.

Holick MF (1995) Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 61:638S–645SPubMed

24.

Group LLS (2006) Laboratory test information guide. London Health Sciences Centre, London

25.

Calatayud M, Jodar E, Sanchez R, Guadalix S, Hawkins F (2009) Prevalence of deficient and insufficient vitamin D levels in a young healthy population. Endocrinol Nutr 56:164–169CrossRefPubMed

26.

Lamberg-Allardt CJ, Outila TA, Karkkainen MU, Rita HJ, Valsta LM (2001) Vitamin D deficiency and bone health in healthy adults in Finland: could this be a concern in other parts of Europe? J Bone Miner Res 16:2066–2073CrossRefPubMed

27.

Adams ND, Gray RW, Lemann J Jr (1979) The effects of oral CaCO₃ loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults. J Clin Endocrinol Metab 48:1008–1016CrossRefPubMed

28.

Erickson SB, Cooper K, Broadus AE, Smith LH, Werness PG, Binder HJ, Dobbins JW (1984) Oxalate absorption and postprandial urine supersaturation in an experimental human model of absorptive hypercalciuria. Clin Sci (Lond) 67:131–138

29.

Lindsjo M, Danielson BG, Fellstrom B, Norheim I, Wide L, Ljunghall S (1992) Parathyroid function in relation to intestinal function and renal calcium reabsorption in patients with nephrolithiasis. Scand J Urol Nephrol 26:55–64CrossRefPubMed

30.

D’Angelo A, Calo L, Cantaro S, Giannini S (1997) Calciotropic hormones and nephrolithiasis. Miner Electrolyte Metab 23:269–272PubMed

31.

McKane WR, Khosla S, Burritt MF, Kao PC, Wilson DM, Ory SJ, Riggs BL (1995) Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause—a clinical research center study. J Clin Endocrinol Metab 80:3458–3464CrossRefPubMed

32.

Nordin BE, Need AG, Morris HA, Horowitz M (1999) Biochemical variables in pre- and postmenopausal women: reconciling the calcium and estrogen hypotheses. Osteoporos Int 9:351–357CrossRefPubMed

33.

Domrongkitchaiporn S, Ongphiphadhanakul B, Stitchantrakul W, Chansirikarn S, Puavilai G, Rajatanavin R (2002) Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen. Maturitas 41:149–156CrossRefPubMed

34.

Mattix Kramer HJ, Grodstein F, Stampfer MJ, Curhan GC (2003) Menopause and postmenopausal hormone use and risk of incident kidney stones. J Am Soc Nephrol 14:1272–1277CrossRefPubMed

35.

Lee YH, Huang WC, Chiang H, Chen MT, Huang JK, Chang LS (1992) Determinant role of testosterone in the pathogenesis of urolithiasis in rats. J Urol 147:1134–1138PubMed

36.

Lee YH, Huang WC, Huang JK, Chang LS (1996) Testosterone enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats. J Urol 156:502–505CrossRefPubMed

37.

Kuczera M, Kiersztejn M, Kokot F, Klin M (1993) Behavior of sex hormone and gonadotropin secretion in men with active nephrolithiasis. Endokrynol Pol 44:539–547PubMed

38.

Fan J, Chandhoke PS, Grampsas SA (1999) Role of sex hormones in experimental calcium oxalate nephrolithiasis. J Am Soc Nephrol 10(Suppl 14):S376–380PubMed

39.

Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C, Toma H (2001) The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol 166:1078–1082CrossRefPubMed

40.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59:2290–2298PubMed

41.

Parks JH, Coe FL (1986) A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 30:85–90CrossRefPubMed

Titel: An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors
verfasst von: Nasser Shakhssalim
Kobra Roohi Gilani
Mahmoud Parvin
Peyman Mohammadi Torbati
Amir H. Kashi
Mohaddeseh Azadvari
Banafsheh Golestan
Abbas Basiri
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Urolithiasis / Ausgabe 1/2011
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-010-0276-3

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

An assessment of parathyroid hormone, calcitonin, 1,25 (OH)₂ vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors

Abstract

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Effect of uropathogens on in vitro encrustation of polyurethane double J ureteral stents

Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage

Antibiotics therapy was effective in preventing bilateral staghorn renal matrix stones

Consumption of krill protein concentrate prevents early renal injury and nephrocalcinosis in female Sprague–Dawley rats

Prediction of outcome of extracorporeal shock wave lithotripsy in the management of ureteric calculi

Specific management of acute renal failure caused by an upper ureteral stone in a solitary pelvic kidney

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie